152 related articles for article (PubMed ID: 22871469)
1. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
Zhou J; Roh JW; Bandyopadhyay S; Chen Z; Munkarah AR; Hussein Y; Alosh B; Jazaerly T; Hayek K; Semaan A; Sood AK; Ali-Fehmi R
Gynecol Oncol; 2013 Feb; 128(2):344-8. PubMed ID: 22871469
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
3. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].
Guo ZL; Chen K; Wang XQ; Hu W
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347
[TBL] [Abstract][Full Text] [Related]
4. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase overexpression and its impact on human osteosarcoma.
Ren K; Lu X; Yao N; Chen Y; Yang A; Chen H; Zhang J; Wu S; Shi X; Wang C; Sun X
Oncotarget; 2015 Oct; 6(31):31085-103. PubMed ID: 26393679
[TBL] [Abstract][Full Text] [Related]
6. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
Liu DC; Yang ZL
Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Zhang Q; Wang H; Wei H; Zhang D
Int J Clin Exp Pathol; 2018; 11(2):831-838. PubMed ID: 31938172
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
[TBL] [Abstract][Full Text] [Related]
11. Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Gabriel B; Hasenburg A; Waizenegger M; Orlowska-Volk M; Stickeler E; zur Hausen A
Int J Gynecol Cancer; 2009 Oct; 19(7):1221-5. PubMed ID: 19823058
[TBL] [Abstract][Full Text] [Related]
12. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma.
Chatzizacharias NA; Giaginis C; Gatzidou E; Tsourouflis G; Sfiniadakis I; Alexandrou P; Theocharis SE
Pathol Oncol Res; 2011 Jun; 17(2):277-85. PubMed ID: 21058027
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase overexpression in endometrial neoplasia.
Livasy CA; Moore D; Cance WG; Lininger RA
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):342-5. PubMed ID: 15536334
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
20. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
